Routine board transition with no red flags. Monitor for any future changes in board composition or R&D committee leadership that could signal strategic shifts.
Price Chart
Executive Summary
Stoke Therapeutics disclosed the resignation of board member Dr. Edward M. Kaye and the immediate appointment of Alexander (Bo) Cumbo as a Class III director. The resignation was not due to any disagreement, and the transition is routine with no material financial impact.
Key Facts
- Edward M. Kaye resigned as Class III director and from the R&D Committee effective September 23, 2026, with no disagreement with the company.
- Alexander (Bo) Cumbo was appointed as Class III director effective September 23, 2026, to fill the vacancy.
- Cumbo will receive an annual cash retainer of $45,000 and an initial stock option to purchase 39,674 shares with a grant date fair value of approximately $724,000.
- Cumbo qualifies as an independent director under SEC and Nasdaq rules.
Financial Impact
Standard director compensation: $45,000 annual cash retainer plus option grant valued at ~$724,000. No material financial impact.
Risk Factors
- Loss of Dr. Kaye's R&D expertise on the board could reduce scientific oversight depth.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-402820 |
| Document: 0001193125-26-402820-index-headers.html | 0001193125-26-402820 |
| Document: 0001193125-26-402820-index.html | 0001193125-26-402820 |
| Document: 0001193125-26-402820.txt | 0001193125-26-402820 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 today | 8-K | $26.35 | awaiting T+60 | awaiting T+60 | $26.35 (+0.00%) |
Oct 21, 2026 8d ago | 144 | $25.70 | awaiting T+60 | awaiting T+60 | $26.35 (−2.53%) |
Sep 30, 2026 29d ago | SC 13G | $26.01 | awaiting T+60 | awaiting T+60 | $26.35 (+1.31%) |
Sep 25, 2026 4w ago | 8-K | $25.50 | awaiting T+60 | awaiting T+60 | $26.35 (+3.33%) |
Aug 18, 2026 10w ago | Insider Cluster | $33.03 | awaiting T+60 | awaiting T+60 | $26.35 (−20.22%) |
Aug 3, 2026 12w ago | 8-K | $31.67 $26.13 | ▲ +17.49% | ▲ +17.28% | $26.35 (+16.80%) |
Aug 3, 2026 12w ago | 424B5 | $31.67 $26.13 | ▲ +17.49% | ▲ +17.28% | $26.35 (+16.80%) |
Jun 30, 2026 17w ago | 8-K | $32.72 $26.11 | ▼ −20.20% | ▼ −23.77% | $26.35 (−19.47%) |
May 7, 2026 25w ago | 8-K | $32.89 $31.67 | ▼ −3.71% | ▼ −8.55% | $26.35 (−19.88%) |
Apr 22, 2026 27w ago | DEFA14A | $34.93 $27.68 | ▼ −20.76% | ▼ −25.77% | $26.35 (−24.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers